linjc16/ctgov huggingface dataset:
Corona And Manual Professions

Study Overview
=================
Brief Summary
-----------------
This observational study will follow the chiropractors and naprapaths in Sweden to study how work environment, health, and economy is changing during the COVID-19 pandemic.

Detailed Description
-----------------
All manual therapists that are members of a professional organization in Sweden will be invited to participate. The study started in November 2020 with follow-ups planned after 3,6 and 12 months. All data-collection is taking place with digital questionnaires. There are three main areas of interest: Work environment (knowledge about viral contageon, protection, availability of protective measures, disturbances in care for patients) Health (physical and psychological, how many caught the virus?) Economy (income, costs, turnover)

Official Title
-----------------
COVID-19 Pandemic and Small Businesses in the Health Care Sector - Work Environment, Health and Economy of Swedish Chiropractors and Naprapaths

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chiropractor or naprapath working in Sweden clinically active belonging to a professional organization Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Work environment | Changes in routines according to the pandemic This includes systematic work environment routines, cleaning, wearing protective gear, not treating patients belonging to certain risk categories, changing appointment scheduling etc. There are no validated questionnaires to examine these concepts, as we have not experienced a pandemic in modern times, so the questions are constructed by the research group. | 12 months | 
| Physical Health -Pain | Physical pain using the Nordic Musculoskeletal Questionnaire | 12 months | 
| Psychological Health -depression | Depression assessed with DASS-21 | 12 months | 
| Psychological Health -sleep | Sleep will be assessed using Karolinska Sleep Questionnaire. | 12 months | 
| Economy | Changes in company turnover. For clinic owners, this measure is assessing income and cost, estimated by clinic owners, There are no validated questionnaires to examine these concepts, as we have not experienced a pandemic in modern times, so the questions are constructed by the research group. | 12 months |
Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

Detailed Description
-----------------
This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Official Title
-----------------
Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Device: The imaging biomarkers determined by MR-PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prior Informed Consent Form At least one measurable tumor, according to RECIST version 1.1. Age > 20 years. ECOG performance status 0 or 1. Life expectancy > 3 months. Confirmed Diagnosis of HCC Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal). Exclusion Criteria: Age <20 years old Pregnancy Contraindication for MRI: claustrophobia or MR non-compatible devices Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre > 2.0) History of other malignancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The recurrence rate at 3 months after treatment |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The overall survival after treatment |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MR/PET, hepatocellular carcinoma, HCC
Clinical Application of MDCT in Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
1) Establish normal value for coronary calcium scoring in Taiwan. 2) Find out the relationship of coronary calcium deposition and coronary artery stenosis. Propose a clinical management guideline based on coronary calcium score. 3) Evaluate sensitivity/specificity of coronary CT angiography and the influence of coronary calcium score on coronary CT angiography. 4) Evaluate the clinical application of myocardial enhancement measurement.

Detailed Description
-----------------
Computed tomography is evolving as a tool for noninvasive diagnosis of coronary artery disease. Coronary calcium deposition amount is an established independent coronary artery disease risk factor. However, coronary artery stenosis seldom occurred in the same location as calcium deposition. With the advent of 16-detector-row multislice spiral CT, direct visualization of coronary artery is possible. But it remains a great challenge to obtain diagnostic quality image in the beating heart. Small distal vessels may not be adequately visualized. Artifacts from severe calcification or coronary stent may render diagnosis difficult. The clinical implication of coronary calcium score, indication of coronary CT angiography and myocardial enhancement measurement should be further studied. The purposes of this study are: 1) Establish normal value for coronary calcium scoring in Taiwan. 2) Find out the relationship of coronary calcium deposition and coronary artery stenosis. Propose a clinical management guideline based on coronary calcium score. 3) Evaluate sensitivity/specificity of coronary CT angiography and the influence of coronary calcium score on coronary CT angiography. 4) Evaluate the clinical application of myocardial enhancement measurement.

Official Title
-----------------
Clinical Application of 16-Detector Row Computed Tomography in Coronary Artery Disease

Conditions
-----------------
Coronary Arteriosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: coronary artery disease admitted for coronary angiography Exclusion Criteria: Heart failure, irregular heart rate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Effect of Intubation Method on Outcome of Cervical Spine Surgery

Study Overview
=================
Brief Summary
-----------------
The specific aim of this study is to demonstrate that inserting a breathing tube using a standard laryngoscope with the patient fully anesthetized is a safe and effective means of securing the airway in a patient with cervical spine disk herniation or stenosis. The two groups compared are composed of those who are intubated with direct laryngoscopy and those who are intubated with a fiberoptic scope.

Conditions
-----------------
Cervical Pain

Intervention / Treatment
-----------------
* Procedure: cervical spine surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age for cervical disk herniation or cervical spine surgery by either Drs Snow or Lavyne from 1998-2006. Exclusion Criteria: Unstable (broken) cervical spine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: cervical spine surgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate serum thymidine kinase 1 (TK1) activity as a marker for solid tumors and more specifically in: preoperative testing for prediction of disease recurrence and survival; follow-up after surgical removal of the original tumor for early detection of disease recurrence and in monitoring therapy as a surrogate marker of tumor response.

Detailed Description
-----------------
Thymidine kinase 1 (TK1) is a metabolic enzyme catalyzing the ATP-dependent phosphorylation of thymidine to thymidine monophosphate followed by its utilization in DNA synthesis. It has been demonstrated that activity of TK1 in the serum of cancer patients corresponds to the amount of dividing tumor cells. Several clinical investigations clearly showed that abnormal TK1 levels indicate tumor growth. In breast cancer, serum TK1 was shown to predict increased risk of recurrence following surgery and may be a good marker for monitoring the response to therapy. The measurements of TK1 were useful as a prognostic and monitoring factor in patients with NSCLC. Unfortunately, all previously used assays measuring TK1 activity showed relatively low analytical sensitivity. Recently, the novel high sensitive non-radioactive TK1 assay (DiviTum) has been developed. With this assay tumour growth may be detected at an earlier stage of disease and smaller amounts of residual disease may be detected during and after therapy.

Official Title
-----------------
Evaluation of Serum Thymidine Kinase Activity in Diagnosis,Prognosis and Monitoring of Treatment in Patients With Solid Tumors

Conditions
-----------------
Solid Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with colon, breast, prostate and lung cancer before and during treatment Exclusion Criteria: pregnant women; patients with generalized CMV and HZV infections; patients with severe rheumatoid arthritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>colon cancer, prostate cancer, lung cancer, ovarian cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thymidine Kinase 1 activity, diagnosis, prognosis, follow-up
The Characteristics of Regional Bone Quality in the Cervical Vertebrae Considering BMD

Study Overview
=================
Brief Summary
-----------------
Data of CT images and the femoral neck BMD were obtained from 99 patients who underwent the cervical CT and BMD simultaneously (the gap of both studies was within 6 months) from April 2009 to December 2014. There were 52 females and 47 males. The mean age was 63.7 year (female: 63.4 years, male: 64.1; range 32-86 years). The patient was excluded who had any destructive pathology or severe spondylosis in the cervical pedicle and the cervical lateral mass. Patients were divided into three groups according to femoral neck BMD (Group A, T-score ≥-1; Group B, -2.5<T-score<-1.0; Group C, T-score≤-2.5). Group A had normal BMD patients, Group B had lower normal patients including osteopenic patients and Group C presented osteoporotic patients. The mean HU numbers of cortical bone area in the vertebral canal (cHU, the medial wall of the lateral mass), the posterior wall of transverse foramen (fHU), the medial (mHU), lateral wall (lHU) and trabecular area of pedicle (pHU) were measured on the axial CT images in clinical images.

Official Title
-----------------
The Characteristics of Regional Bone Quality in the Cervical Vertebrae Considering BMD

Conditions
-----------------
Cortical Bone Thickness

Intervention / Treatment
-----------------
* Other: Cortical Bone thickness and Hounsfield unit (HU) numbers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent the cervical CT and BMD simultaneously (the gap of both studies was within 6 months) Exclusion Criteria: Who had any destructive pathology or severe spondylosis in the cervical pedicle and the cervical lateral mass.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>T-score ≥-1 | Other: Cortical Bone thickness and Hounsfield unit (HU) numbers<br>* Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD<br>|
| Group B<br>-2.5<T-score<-1.0 | Other: Cortical Bone thickness and Hounsfield unit (HU) numbers<br>* Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD<br>|
| Group C<br>T-score≤-2.5 | Other: Cortical Bone thickness and Hounsfield unit (HU) numbers<br>* Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cortical bone Thickness |  | two weeks | 
| HU number |  | two weeks |
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection

Study Overview
=================
Brief Summary
-----------------
The purpose of this study to examine the efficacy and safety of cycling treatment of deoxyspergualin in renal transplant patients with biopsy-proven chronic rejection.

Detailed Description
-----------------
The primary aim of this study is to investigate the efficacy of deoxyspergualin after the completion of 6 cycles treatment. The efficacy valuables are histological findings in renal grafts, renal function, proteinuria, graft survival, anti-HLA antibody. The safety data are also evaluated in the study.

Official Title
-----------------
Pilot Study of Cycling Treatment of Deoxyspergualin in Biopsy-proven Chronic Rejection of Kidney Transplantation

Conditions
-----------------
Chronic Rejection

Intervention / Treatment
-----------------
* Drug: Deoxyspergualin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic rejection defined by Banff 2007 criteria Exclusion Criteria: Patients who have recurrent renal diseases and virus-associated renal diseases Patients who have initial WBC < 4,000, neutrophil < 1,000 , platelet < 50,000 or Hb < 8g Patients who have acute or chronic infection

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Deoxyspergualin, Treatment,<br> | Drug: Deoxyspergualin<br>* 100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.<br>* Other names: Spanidin, gusperimus hydrochloride;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histopathological findings by Banff criteria |  | 6 month after treatment initiation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function, proteinuria, graft survival, anti-HLA antibody, adverse events, serious adverse events (SAE) |  | 6 and 12 months after treatment initiation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic rejection, Kidney, Transplantation, Immunosuppressive
Financial Incentives to Improve Medication Adherence

Study Overview
=================
Brief Summary
-----------------
Medication adherence is a challenge in all of medicine and is associated with multiple negative outcomes. Strategies to better measure and enhance adherence to medication are urgent and necessary to minimize unwanted health outcomes, hospitalizations, poorer quality of life and excessive costs for individuals, insurers and caregivers. Recently, behavioral economics-based approaches have emerged as a promising tool to address this unmet need, but its effectiveness in oral antipsychotic treatment remains to be assessed. For this project, investigators will use an app that offers financial incentives to increase compliance for patients with chronic diseases. Investigators intend to enroll 25 patients in a pilot project to assess feasibility of offering financial incentives to improve medication adherence in severe mental illness.

Official Title
-----------------
Financial Incentives to Improve Medication Adherence: a Pilot Study

Conditions
-----------------
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression

Intervention / Treatment
-----------------
* Other: Wellth - Financial Incentives


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Psychiatric patients with suspected or confirmed poor oral medication adherence. Age 18-80 years old English speaking, since the app being used is only available in English Owning a Smartphone, since the app requires a Smartphone to work Willing and able to participate. Exclusion Criteria: Acute anger to self or others as per investigator assessment Unwilling or unable to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>This study has only one arm. All patients enrolled will take part in the experimental arm. | Other: Wellth - Financial Incentives<br>* Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in medication adherence rate | Adherence rate will be measured as pills missed/pills prescribed | Between baseline and study completion (10 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
financial incentives, medication adherence, severe mental illness
Outcome After Out of Hospital Cardiac Arrest in Bern, Switzerland

Study Overview
=================
Brief Summary
-----------------
Sudden cardiac arrests is one of the most frequent causes of death. In Switzerland every year 8000-10.000 people suffer from a cardiac arrest. The EuReCa ONE Study showed regional differences in incidence and chances of survival after cardiac arrests in Europe. The current European Resuscitation Council (ERC) resuscitation guidelines 2015 recommend extracorporeal membrane oxygenation (ECMO) as treatment option for therapy refractory out-of-hospital cardiac arrests (OHCA). ECMO used under cardiopulmonary resuscitation (CPR) is called eCPR (extracorporeal CPR). In the year 2018 eCPR is started to be used in Bern, Switzerland. This study investigates retrospectively the survival and neurologic outcome of patients after OHCA in the region of Bern, Switzerland from 2015-2018. The data will be used as baseline for a prospective evaluation of eCPR cases. The prospective Evaluation of e CPR will last from 2018 - 2022.

Official Title
-----------------
Outcome After Out of Hospital Cardiac Arrest in Bern, Switzerland

Conditions
-----------------
Resuscitation, Outcome, Fatal, Out-Of-Hospital Cardiac Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All OHCA in the region of Bern, Switzerland in the year 2015-2017 Exclusion Criteria: if patient has previously declined to be included in a study (advance directive)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurologic Outcome after 30 days | CPC 1 - 5 (Cerebral Performance Category Scale) | 30 days after OHCA |